We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Management and outcomes of paediatric patients on emicizumab prophylaxis undergoing surgical procedures: Experience from a large haemophilia centre in the UK.
- Authors
Hassan, Eman; Motwani, Jayashree
- Abstract
We performed retrospective study based on the data of all haemophilia A patients on emicizumab prophylaxis, treated at the haemophilia unit at Birmingham Children's Hospital. At time of surgery, all patients were on emicizumab for a period ranging from 2 to 62 weeks (Median [Interquartile range] 38.0 [18.79-54.57]), and dose of 3 mg/kg every 2 weeks except patient#12who was on the weekly loading doses, number of doses prior to surgery ranged 2-35 doses(Median (Interquartile range) 23.0 (14.0-30.0)). Only three patients (patient#2, #6 and#13) required peri-operative hospital admission, patient#2 #6 were admitted due to central lines infection, and subsequently lines were emergently removed.
- Subjects
UNITED Kingdom; OPERATIVE surgery; EMICIZUMAB; CHILD patients; TREATMENT effectiveness; BISPECIFIC antibodies; BONE grafting; PALATE surgery
- Publication
Haemophilia, 2021, Vol 27, Issue 5, pe620
- ISSN
1351-8216
- Publication type
Article
- DOI
10.1111/hae.14358